Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
5080292
Reference Type
Journal Article
Title
Low concentrations of perfluorooctane sulfonate repress osteogenic and enhance adipogenic differentiation of human mesenchymal stem cells
Author(s)
Liu, W; Qin, H; Pan, Y; Luo, F; Zhang, Z
Year
2019
Is Peer Reviewed?
1
Journal
Toxicology and Applied Pharmacology
ISSN:
0041-008X
EISSN:
1096-0333
Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
Location
SAN DIEGO
Volume
367
Page Numbers
82-91
Language
English
PMID
30738844
DOI
10.1016/j.taap.2019.02.001
Web of Science Id
WOS:000460494100009
URL
https://linkinghub.elsevier.com/retrieve/pii/S0041008X19300420
Exit
Abstract
Humans are exposed to perfluorooctane sulfonate (PFOS) from sources of both continuing discharges and environmental legacies, and the health effects of low dose exposure remain unknown. We assessed the effects of PFOS at 0.2-200 nmol/L on osteogenic and adipogenic differentiation of human bone marrow-derived mesenchymal stem cells (hBMSCs). PFOS affected hBMSCs differentiation in a nonmonotonic dose-response relationship, where the effects peaked at 100 nmol/L. PFOS repressed calcium deposition on day 14 of osteogenic differentiation. The molecular osteogenic biomarkers, osteopontin, osteonectin and osteocalcin, and the transcription factor β-catenin, were also decreased on differentiation day 7. In hBMSCs co-treated by PFOS and WNT signaling agonist, LiCl, the osteogenic marker levels were higher than those treated by PFOS alone. Moreover, the osteogenic effect of PFOS was repressed by DKK1, the WNT signaling antagonist. PFOS additionally supported the receptor activator of nuclear factor κB ligand/osteoprotegerin ratio. In contrast, PFOS enhanced adipogenesis in regard to lipid droplet formation and marker gene expression of PPARγ, CCAAT/enhancer-binding protein-α (C/EBPα), lipoprotein lipase and leptin. Microarray analysis identified 597 differentially expressed genes at p < .05 and log2 (fold change) > 0.3. These results demonstrated that PFOS repressed osteogenesis and enhanced adipogenesis, which could well explain the homeostatic imbalance seen in human bone associated with exposure to PFOS.
Keywords
Perfluoroalkyl compounds; Bone health; Stem cells; Multipotent differentiation; Microarray analysis
Tags
PFAS
•
Additional PFAS (formerly XAgency)
•
Expanded PFAS SEM (formerly PFAS 430)
Litsearch: September 2019
PubMed
Web of Science
Not prioritized for screening
Perfluorooctane
•
PFAS 150
Literature Search Update December 2020
PubMed
WOS
Literature Search August 2019
PubMed
Web of Science
Not prioritized for screening
Perfluorooctane
Perfluorooctanesulfonic acid
•
PFOA (335-67-1) and PFOS (1763-23-1)
Literature Search Update (2013-2019)
PubMed
WOS
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity